title: [POSITIVE EFFECTS OF MODERN IMMUNOCORRECTION ACCORDING TO THE ANALYSIS OF CYTOKINES AND SLPI IN PATIENTS WITH PYELONEPHRITIS].
abstract: The peculiarities of cytokines as compounds of immunogenesis are shown in the patients having acute (A) and chronic (Ch) pyelonephritis (PN). The combination of antibacterial therapy with Nukleinat and Galavit promotes the positive changes of cytokin-producing ability of immunocompetent cells and decrease in the level of proinflammation cytokines in blood and urine, secretory leucocyte protease inhibitor (SLPI) in urine. In children with PN and adult patients with diagnostically elevated titres of antibodies (IgG) to Herpes simplex virus, Cytomegalovirus are shown the positive effects of Kanephron® H and Proteflazidum, accordingly. Clinico-immunological effects of immunomodulators testify to the expediency of this usage in complex therapy with the aim to modulate the cytokine link of immunity for improvement of the effective treatment in APN and the protection against aggravation of kidney functioning in ChPN.
authors.forename: V E
authors.initials: VE
authors.lastname: Driyanska
authors.forename: G N
authors.initials: GN
authors.lastname: Drannik
authors.forename: N M
authors.initials: NM
authors.lastname: Stepanova
authors.forename: L O
authors.initials: LO
authors.lastname: Lebed
authors.forename: V T
authors.initials: VT
authors.lastname: Kruglikov
authors.forename: V V
authors.initials: VV
authors.lastname: Driyanska
authors.forename: O V
authors.initials: OV
authors.lastname: Lavrenchuk
authors.forename: N A
authors.initials: NA
authors.lastname: Kalinina
authors.forename: F Z
authors.initials: FZ
authors.lastname: Gaisenuk
mesh_terms: D000208:Acute Disease; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D002648:Child; D002908:Chronic Disease; D016207:Cytokines / Q000235:genetics / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D005260:Female; D015870:Gene Expression; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007369:Interferon Inducers / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008165:Luminol / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009696:Nucleic Acids / Q000627:therapeutic use; D028321:Plant Preparations / Q000627:therapeutic use; D011704:Pyelonephritis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000235:genetics / Q000276:immunology
chemical_list: D000900:Anti-Bacterial Agents; D000975:Antioxidants; D016207:Cytokines; D007155:Immunologic Factors; D007369:Interferon Inducers; D009696:Nucleic Acids; D028321:Plant Preparations; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; C555878:kanefron H; D008165:Luminol; C013683:sodium nucleinate; C511308:sodium luminolate